SOUTH SAN FRANCISCO, Calif., Aug. 4, 2014 /PRNewswire/ -- Velocity Pharmaceutical Development, LLC ("VPD") and Tigercat Pharma, Inc., ("Tigercat") today announced that the first patient has been dosed in a double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of VPD-737 (serlopitant), administered orally in patients with prurigo nodularis. Separately, VPD is also conducting a Phase II clinical trial in the United States evaluating VPD-737 in patients with chronic pruritus.
Dr. Edward Schnipper, Tigercat's Chief Medical Officer, stated "We are delighted to announce that the first patient has been dosed in this important Phase II study. Prurigo nodularis is a debilitating disease and the current standard of care does not effectively address this condition. We believe VPD-737 is a promising pharmacological option and we are eager to see results from this study, which along with data from our chronic pruritus study, will be available in 2015."
The trial is a double-blind, placebo-controlled Phase II study in sixty patients with prurigo nodularis, an orphan disease. The study is designed to determine the safety, tolerability, and efficacy of VPD-737, an NK-1 receptor antagonist, and is underway at four sites in Germany. Patients in the study will receive either 5 mg of VPD-737 or placebo, taken once daily, for a period of eight weeks.
VPD-737 was exclusively licensed by Merck to VPD in 2012.
About Tigercat Pharma, Inc.
Tigercat Pharma, Inc., is a largely "virtual" company which was created to hold the ownership of the VPD-737 development program. Tigercat is funded by Velocity Pharmaceutical Holdings, LLC, and Remeditex Ventures, LLC. The VPD-737 development program is managed under contract by VPD.
About Velocity Pharmaceutical Development, LLC
VPD is a
|SOURCE Velocity Pharmaceutical Development, LLC|
Copyright©2014 PR Newswire.
All rights reserved